New Delhi, Aug 3 (PTI) Drug firm Jubilant Life Sciences on Monday said it has launched the generic version of antiviral drug remdesivir in India for the treatment of COVID-19 patients.

The injectable drug, under the brand name 'JUBI-R', is priced at Rs 4,700 per vial of 100 mg.

Also Read | Punjab Hooch Tragedy: Death Toll Rises to 105, Amritsar Police Arrests 12 More Accused.

The company will make the drug available to over 1,000 hospitals providing COVID-19 treatment, Jubilant Life Sciences said in a statement.  

In order to increase accessibility of the drug to patients below the poverty line and to front-line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of the Jubilant Group, is launching programs in India aimed at its distribution, it added.

Also Read | West Bengal Reports 53 New COVID-19 Fatalities: Live News Breaking And Coronavirus Updates on August 3, 2020.

"We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market and in other countries," Jubilant Pharma Chairman and MD Shyam S Bhartia and Co-Chairman Hari S Bhartia said in the statement.

The company's ability to launch this product in such short timelines highlights "our R&D and manufacturing capabilities and our continued commitment to provide leading healthcare solutions", they added.  

In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences Inc that granted it the right to register, manufacture and sell the US-based firm's investigational drug remdesivir in 127 countries, including India, the statement said.   

On July 20, 2020, the company received approval from the Drug Controller General of India (DCGI) to manufacture and market remdesivir for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19, it added. 

The drug will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner, the statement said.   

Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the United States Food and Drug Administration (USFDA) for the treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalised with severe disease, it added.  

Shares of Jubilant Life Sciences closed at Rs 862.30 per scrip on BSE, up 8.42 per cent from its previous close. PTI AKT ABM ABM 08032113 NNNNe good way to look at it is the first inning becomes the third inning,” Reds manager David Bell said before Sunday's games.

“I remember in the minor leagues seeing a lot of pitching gems in the seven-inning games, so I think it's an opportunity for starting pitchers — to really from pitch one, you can see the end a little bit quicker.”

Sure enough, Cincinnati's Trevor Bauer threw a two-hit shutout in the second game against Detroit. But that effort took 2 hours, 36 minutes, and the opener was played in 2:25. That would feel short if it were a nine-inning game, but it wasn't like the Reds and Tigers just breezed through the day.

The Tigers have another doubleheader scheduled for Wednesday against St. Louis — if the Cardinals can play.

There was a time when doubleheaders were a constant presence in the majors. The Boston Braves played a record 46 of them in 1945, according to SportRadar. But last year, there were only 33 doubleheaders total, and the New York Yankees led the way with seven.

Now these seven-inning doubleheaders are a possibility every team should be prepared to face.

“We'll do our best when that's in front of us, try and win those games. Obviously, it's a little bit different,” Yankees manager Aaron Boone said.

“You know, it's hard to know how you attack those days until you're there and what the day before looked like, what the days coming up look like — who's on the mound those days? Those are all things you kind of factor in as you get closer. I don't know how much necessarily changed, other than it's a little bit different circumstances that we have to navigate.” (AP)

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)